We create a better life through integrity and innovation.
We put patient and consumer well-being at the forefront of everything we do. Guided by cutting-edge scientific research and a focus on market needs, we continuously innovate to deliver exceptional quality in our products and services, improving lives worldwide.
News
Grand Pharma’s subsidiary launched innovative dual‑mechanism nasal spray Ryaltris® in China, filling the clinical gap for allergic rhinitis combination therapies, especially for patients aged 6+. It enriches the firm’s respiratory portfolio and supports standardized, precise treatment while addressing high disease prevalence.
Sinclair has partnered with Harvard Medical School’s Massachusetts General Hospital to introduce the renowned Magic Wand Initiative (MWI) to Asia for the first time. The collaboration is set to inject new momentum into the innovative development of the medical aesthetics industry in the Asia-Pacific region.
From October 17 to 19, 2024, Sinclair once again set sail in the vibrant, artistic city of Barcelona, bringing a wealth of academic enthusiasm to the event. Joined by nearly a thousand global medical aesthetic practitioners, industry leaders, and media representatives, Sinclair co-hosted the World Expert Meeting 2024 (WEM)–the Sinclair Global Medical Aesthetics Summit.
Focus
On November 3rd, the Ministry of Industry and Information Technology of China announced the list of National Technology Innovation Demonstration Enterprises for 2022. Grand Pharmaceuticals (China) Co., Ltd. (hereinafter referred to as “Grand Pharma”) was honored and…
On June 19, 2022, Grandpharma (0512.HK) announced that a "nuclear weapon" innovative medical product to treat liver malignant tumors -- SIR-Spheres® yttrium-90 microsphere injections (trademark in Chinese charters: 易甘泰®, read as “Yigantai”) …
On April 8, 2022, a new production base (West High-tech Zone) for blood products of Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.("Yuanda Shuyang"), a wholly-owned subsidiary of Yuanda Life Science Group Co., Ltd, was officially put into operation,
Focus
On November 3rd, the Ministry of Industry and Information Technology of China announced the list of National Technology Innovation Demonstration Enterprises for 2022. Grand Pharmaceuticals (China) Co., Ltd. (hereinafter referred to as “Grand Pharma”) was honored and…
On June 19, 2022, Grandpharma (0512.HK) announced that a "nuclear weapon" innovative medical product to treat liver malignant tumors -- SIR-Spheres® yttrium-90 microsphere injections (trademark in Chinese charters: 易甘泰®, read as “Yigantai”) …
On April 8, 2022, a new production base (West High-tech Zone) for blood products of Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.("Yuanda Shuyang"), a wholly-owned subsidiary of Yuanda Life Science Group Co., Ltd, was officially put into operation,
Group
Our growth is driven by regulatory compliance, operational excellence, and an enduring commitment to life-changing breakthroughs.
Businesses
Innovation is the key driver of our growth. Aligned with strategic objectives and focused on our core business areas, we build our competitive edge on responsibility and a commitment to progress.